country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P10792A

Copy Link Print Information

HYNIC-H6F

HYNIC-H6F is a SPECT imaging probe with binding specificity for human epidermal growth factor receptor 2 (HER2) domain II (IC₅₀ = 11 nM). HYNIC-H6F accumulates in HER2-positive breast cancer xenografts via receptor-mediated uptake, while shows low uptake in HER2-negative breast cancer xenografts. HYNIC-H6F enables non-invasive detection of HER2-positive breast cancer in mouse models and allows evaluation of HER2 expression levels without blocking interference. HYNIC-H6F can be used in breast cancer-related research.

For research use only. We do not sell to patients.

Formula: C₆₄H₈₂N₁₄O₁₃
Molecular Weight:1255.42

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Custom Peptide Synthesis

HYNIC-H6F Chemical Structure

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

HER2

11 nM (IC₅₀)

All EGFR Isoforms :

In Vitro

HYNIC-H6F (11 nM; 2 h) binds specifically to HER2 on MDA-MB-453 cells with an IC₅₀ of 11 nM, with minimal impact on binding affinity from HYNIC conjugation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

99mTc-HYNIC-H6F (0.37-37 MBq; i.v. via tail vein; single dose) specifically accumulates in HER2-positive MDA-MB-453 breast cancer xenografts, reaching a peak imaging-quantified uptake of 3.58 %ID/g at 30 min after injection, with binding blocked by excess unlabeled H6F^[1].
99mTc-HYNIC-H6F (0.37-37 MBq; i.v. via tail vein; single dose) exhibits minimal accumulation in HER2-negative MDA-MB-231 breast cancer xenografts, with a biodistribution-quantified uptake of 0.99 %ID/g at 30 min after injection that is significantly lower than uptake in HER2-positive tumors^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

Molecular Weight 1255.42
Formula C₆₄H₈₂N₁₄O₁₃
Sequence

{HYNIC}-Tyr-Leu-Phe-Phe-Val-Phe-Glu-Arg
Sequence Shortening

{HYNIC}-YLFFVFER
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Li L, et al. SPECT/CT imaging of the novel HER2-targeted peptide probe 99mTc-HYNIC-H6F in breast cancer mouse models. Journal of Nuclear Medicine. 2017 May 1;58(5):821-6.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Get Quote In-stock